WEBULL
WebtradeDownload

Xenon Pharmaceuticals (XENE) Could Be 23% Undervalued As Epilepsy Growth Narrative Holds

Simply Wall St · 1d ago

Xenon Pharmaceuticals (NasdaqGM:XENE) is back in focus after reporting a second quarter net loss of US$110.74 million and preparing to present at Stifel’s 2026 Biotech Summer Summit on August 10 in Newport.

See our latest analysis for Xenon Pharmaceuticals.

Despite the wider loss, Xenon Pharmaceuticals shares have cooled in the last month with a 1-month share price return of down 8.66% and a 7-day move of down 1.59%. However, the 90-day share price return of 16.09% and 1-year total shareholder return of 63.09% point to momentum that has been building over a longer window.

If the recent earnings update has you reassessing your watchlist, this can be a good moment to scan for other healthcare names using the 42 healthcare AI stocks

The recent pullback in Xenon Pharmaceuticals after a steep 1-year run leaves you weighing two options: lock in exposure at today’s level, or wait for a deeper reset. To judge that trade off, the valuation picture comes next.

Most Popular Narrative: 22.6% Undervalued

Compared with the last close at $62.35, the most followed Xenon Pharmaceuticals narrative points to a fair value of $80.56, which implies a sizeable valuation gap built on clinical and earnings expectations.

Advancing azetukalner toward multiple late stage readouts in focal onset and generalized seizures positions Xenon to tap a growing pool of refractory epilepsy patients who need better tolerated, easy to use therapies. This supports a step change in revenue on approval and later expands earnings as fixed R&D is leveraged.

Read the complete narrative.

Want to see how a single epilepsy program underpins this jump in fair value? The narrative leans on aggressive revenue build, richer profit margins, and a premium future earnings multiple.

Result: Fair Value of $80.56 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Xenon Pharmaceuticals still faces real risks if late stage azetukalner data disappoints, or if rival epilepsy therapies show stronger efficacy and limit future uptake.

Find out about the key risks to this Xenon Pharmaceuticals narrative.

Another View on Xenon Pharmaceuticals Valuation

The analyst narrative frames Xenon Pharmaceuticals as 22.6% undervalued at $62.35 versus a fair value of $80.56. A different perspective comes from the P/B ratio. XENE trades at 4.9x book value, which is described as expensive compared with the US Biotechs average of 2.4x, yet far lower than a peer average of 68.1x. That gap highlights a range of potential valuation outcomes. Which side of that spread do you think the stock ultimately gravitates toward?

See what the numbers say about this price — find out in our valuation breakdown.

NasdaqGM:XENE P/B Ratio as at Aug 2026
NasdaqGM:XENE P/B Ratio as at Aug 2026

Next Steps

With mixed signals around Xenon Pharmaceuticals valuation and outlook, it makes sense to move quickly and review the full picture for yourself. To see both sides of the story in one place, read the 3 key rewards and 4 important warning signs

Looking for more investment ideas beyond Xenon Pharmaceuticals?

If Xenon Pharmaceuticals has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to surface other opportunities that fit your investing style.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.